In a challenging environment, SCOR meets its targets and records net income of EUR 206 million in the first half 2012
- FR
- EN
In a challenging environment, SCOR meets its targets and records net income of EUR 206 million in the first half 2012
In a challenging environment, SCOR meets its targets and records net income of EUR 206 million in the first half 2012.
Mémoire présenté par Sébastien de Valeriola en vue de l’obtention du master en sciences actuarielles (juin 2012).
How long will men in France who are now 75 live? Or women? Or men or women who are now 60 or 40? Or men and women in Denmark, Germany, Italy, Japan or the United States?
Urological cancers, i.e. of the kidney, bladder and prostate, have an estimated incidence of about 100,000 new cases each year in France.
Urological cancers, i.e. of the kidney, bladder and prostate, have an estimated incidence of about 100,000 new cases each year in France.
Urological cancers, i.e. of the kidney, bladder and prostate, have an estimated incidence of about 100,000 new cases each year in France.
Urological cancers, i.e. of the kidney, bladder and prostate, have an estimated incidence of about 100,000 new cases each year in France.
This article proposes a mathematical modeling of longevity and an analysis of longevity risk in the field of demographics and life insurance.
SCOR Global Life's Embedded Value results of 2011.
SCOR's first quarter of 2012 results.
SCOR Global Life Embedded Value reaches EUR 3.3 billion in 2011 (EUR 18.0 per share), continuing to provide the SCOR group with significant earnings and strong capital repatriation.
Pagination